updat mf anemia data initi phase
quick read sale strengthen
analyst certif import disclosur see
updat mf anemia data initi phase
updat interim result present yesterday luspatercept lu myelofibrosis-associ anemia increment
posit vs confer abstract opinion among newli reveal inform regard patient mark risk
level entri heavi prior therapeut histori long durat diseas indic rel challeng popul
treatment believ add strength efficaci initi report also note announc
sunday night intent initi studi lu inhibitor transfusion-depend patient tf-dep
begin next year recap call morn emphas need anemia treatment note reblozyl
launch -thalassemia solid start special sale repres back bmy/celg sale forc
quick read sale strengthen
share outperform-r trade markedli higher today follow better expect fiscal
nov report compani post earlier morn
late jun lift rate outperform note upon prospect commerci sale
growth chain remain elev follow signific infrastructure-rel invest due still low market
penetr upon view time dynam help underpin multipl expans share today
above-plan nov announc goe long way help support posit stanc
ep rose top street estim upon total compani domest comp sale
growth flat gross margin year-on-year commerci sale expans track
follow today ralli thu far share share easili outpac gain
 opco consum growth e-commerce coverag respect
review close stanc share return comprehens commentari due cours
oppenheim co inc seek busi compani cover research report result
investor awar firm may conflict interest could affect object report
investor consid report singl factor make invest decis
publish date recommend contain report found access disclosur http //
report produc decemb estimate dissemin decemb estimate
compani mention report
import disclosur footnot compani mention report cover oppenheim co inc
stock price decemb
oppenheim co inc rate januari
outperform stock expect outperform within next month
perform stock expect perform line within next month
under-perform stock expect under-perform within next month
rate nr oppenheim co inc maintain coverag stock restrict due potenti
conflict interest
oppenheim co inc rate prior januari
buy anticip appreci within next month and/or total return includ dividend payment
and/or abil share perform better lead stock market averag stock within particular industri sector
neutral anticip share trade near current price gener line lead market averag
due perceiv absenc strong dynam would caus volatil either upsid downsid and/or perform less
well higher rate compani within peer group reader awar rate chang occur neutral
buy aggress trade account might decid liquid posit employ fund elsewher
sell anticip share depreci price within next month due fundament weak
perceiv compani valuat reason expect perform significantli wors equiti within peer group
distribut ratings/ib servic
although invest recommend within three-tier rel stock rate system util oppenheim co inc
correl buy hold sell recommend purpos compli finra rule oppenheim co inc
assign buy rate secur rate outperform hold rate secur rate perform sell rate secur rate
note stock trade consid specul appropri risk toler investor
analyst certif author certifi research report accur state his/her person view subject
secur reflect rate well substanc report author certifi part his/her
compens directli indirectli relat specif recommend view contain research
company-specif disclosur import disclosur includ price chart avail compendium report
